AI assistant
Sending…
Quince Therapeutics, Inc. — Director's Dealing 2020
Mar 12, 2020
34273_dirs_2020-03-12_10bd8e9b-42ba-4d72-afa2-599e1a0697c1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cortexyme, Inc. (CRTX)
CIK: 0001662774
Period of Report: 2019-05-13
Reporting Person: McLoughlin Margaret (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-05-13 | Common Stock | P | 550 | $17.00 | Acquired | 550 | Direct |
More from Quince Therapeutics, Inc.
Regulatory Filings
2026
May 21
Regulatory Filings
2026
May 18
M&A Activity
2026
May 18
Annual Report
2026
Apr 27
Board/Management Information
2026
Apr 22
Capital/Financing Update
2026
Apr 17
Annual Report
2026
Apr 10
Share Issue/Capital Change
2026
Apr 9
Capital/Financing Update
2026
Mar 30
Delisting Announcement
2026
Mar 20